


Click here to find out more with a free DEMO


Hep C 10 Year Forecast:

Datamonitor Healthcare uses a patient-based approach to estimate the size of the hepatitis C market in the US, Japan and 5 major EU markets (France, Germany, Italy, Spain, and the UK).

Datamonitor Healthcare believes that the Hep C market will grow with a compound annual growth rate of **12.6%** from 2013-22.



Hep C market growth: 2013-2022



Rapid increase in 2014 with peak in 2016 due to the entry of interferon free drugs and warehoused patients.

Big drop from 2016 to 2017 due to the exhaustion of the warehoused population.

Slow increase from 2017 to 2022 because of an increase in diagnosis rates.

SALES FORECAST 2013-22:



SET TO FALL:

Incivek	PegIntron
Pegasys	Victrelis



SET TO RISE:

Sovaldi regimens
AbbVie's regimen

Company:

Gilead

AbbVie

Bristol-Myers Squibb

2015 share of market sales

62.5%

22.7%

5.3%

2022 share of market sales

60.1%

19.8%

18.2%

Click here to find out more with a free DEMO

*Data supplied by Datamonitor Healthcare
**Data supplied by Medtrack, 2016